Go M, Kimura M, Yamada S, Kamei K, et al. Safety and Treatment Continuity of Switching Between CDK4/6 Inhibitors for Metastatic Breast Cancer Due to Adverse Events: An Exploratory Single-Center Study in Japan. Oncology 2025 Oct 3:1-17. doi: 10.1159/000548801.
PMID: 41042737